Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTICCA-1 adjuvant chemotherapy trial in resected biliary tract cancer
ACTRN12615001283561Phase 3Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Jan 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, cisplatin and capecitabine in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer (4 arms), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Disease-free survival. Started Jan 2017; status: completed.
02
Drugs
gemcitabinecisplatincapecitabine
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ACTRN12615001283561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615001283561.